Jonathan Rosenberg, MD, from Memorial Sloan Kettering Cancer Center, talks about the development of enfortumab vedotin for urothelial carcinoma, including monotherapy information and combination data.
Jonathan Rosenberg on Enfortumab Vedotin for Urothelial Carcinoma
By The Uromigos - Last Updated: November 11, 2022Post Tags:Uromigos Live-Bladder Cancer
Related Posts
In part 3 of the session, the panel discusses the latest developments in treatments for papillary kidney cancer.
In the second part of the session, the panel highlights some of the most important recent developments in papillary RCC.
In part one of the session, the panelists dive into an in-depth exploration and debate on the results of SUNNIFORECAST.
In the final part of this session, the panel discusses the nuances of re-challenging patients with PD-1 therapies.
The panel discusses the use of immunotherapy, specifically PD-1 based therapies, in renal cell carcinoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.